s	ubstitute for form 1449A/PTO		COMPLETE IF KNOWN				
]	NFORMATION D	ISCLOSURE	Application Number	10/556,805			
A A A A A A A A A A A A A A A A A A A		ADDI ICANIT	Filing Date	November 14, 2005			
No. of the last of	STATEMENT BY .	APPLICANI	First Named Inventor	Tesfaye Biftu et all			
		,	Group Art Unit	AUG 2 7 2007			
	Ase as many sheets t	as necessary)	Examiner Name				
Sheet	1	of 4	Attorney Docket Number	21404P TRADEMARK			

			U.S. P.	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	US 4,386,090		Moinet, et al.	05/31/1983
	2	US 5,939,560		Jenkins, et al.	08/17/1999
	3	US 6,011,155		Vilhauer	01/04/2000
	4	US 6,166,063		Villhauer	12/26/2000
	5	US 6,303,661 B1		Demuth, et al.	10/16/2001
	6	US 6,432,969 B1		Villhauer	08/13/2002
	7	US 6,699,871 B2		Edmondson, et al.	03/02/2004
				X	
	****				
	-				
		-			
		-			
	***********				

	OREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Office				Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY		
	1	PCT	WO 97/49832		Hans-Knoll-Institut Fu	r Naturstoff-Forschung	g E.V. 11/06/1997			
i	2	PCT	WO 98/19998		Novartis AG		05/14/1998			
	3 PCT WO 00/34241 4 PCT WO 01/34594 A1		PCT WO/00/34241		Novartis AG		08/15/2000	06/15/2000		
				Guilford Pharm	aceuticals, Inc.	05/17/2001				
,	5	PCT WO 01/42262 A2			Akzo Nobel N.V.		06/14/2001			
	6	PCT	WO 01/96295 A2		Novartis AG		12/20/200			
	7	PCT	WO 02/02560 A2		Novo Nordisk A/S		01/10/2002	<u> </u>		
	8	8 PCT WO 02/076450 A1		Merck & Co., In	nc.	10/03/2002	1			
	PCT WO 03/000180 A2 Merck & Co., Inc.		nc.	01/03/2003	The state of the s					
	10	PCT	WO 03/000181 A2		Merck & Co., Ir	nc.	01/03/2003	N. S.		
Fxamin Signatu			/Brenda Coleman/			Date Considered	09/14/2008			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Subs	litute for form 1449A/PTC	)		COMPLETE IF KNOWN				
IN	FORMATIO	N DIS	CLOSURE	Application Number	10/556,805			
Mark CT	ATEMENT 1	D37 A D	DY TCANT	Filing Date	November 14, 2005			
101	AIEMENI	BY AP	PLICANI	First Named Inventor	Tesfaye Biftu, et al.			
***				Group Art Unit				
	(See as many sh	eets as n	ecessary)	Examiner Name				
Sheet	2	of	4	Attorney Docket Number	21404P			

		*	ILS, PA	TENT DOCUMENTS	
		U.S. Patent Docume		TENT DOCUMENTS	T /
Examiner Initials*	Cite No.	U.S. Patent Docume	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
				$\overline{}$	

OREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Office	Foreign Patent Document  Number	Kind Code (if known)	Name of Patentee or Applican of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	11	PCT	WO 03/0 <b>3/</b> 2817 A2		Merck & Co., Inc.	10/09/2003			
	12	PCT	WO 2004/007468 A1		Merck & Co., Inc.	01/22/2004			
	13	PCT	WO/2004/032836 A2		Merck & Co., Inc.	04/22/2004			
	14	PCT	WO 2004/043940 A1		Merck & Co., Inc.	05/21/2004			
an y	15	PCT	WO 2004/050022 A2		Merck & Co., Inc.	06/17/2004			
	16	P <b>C</b> T	WO 2004/058266 A1		Merck & Co., Inc.	07/15/2004			
	17	PCT	WO 2004/064778 A2		Merck & Co., Inc.	08/05/2004			
	18/	PCT	WO 2004/069162 A2		Merck & Co., Inc.	08/19/2004			
	19	PCT	WO 2004/110436 A1		Merck & Co., Inc.	12/23/2004			
	20	PCT	WO 2004/112701 A2		Merck & Co., Inc.	12/29/2004			

Examiner /Brenda Coleman/ Date Considered 09/14/2008

									U. S. Patent	and Trademark Offic	æ; U.S DEPARTMENT OF COMMERCE	
s	ubstitute t	or form 1	1449A/PTO							PLETE IF KN	OWN	
INFORMATION DISCLOSURE								olication Number	10/5	10/556,805`		
M. C	STATEMENT BY APPLICANT							ng Date	Nov	November 14, 2005		
JATEMENT DI ATTECANI							Fire	st Named Inventor	Tesf	aye Biftu, et al	ı.	
							Gro	up Art Unit				
	(AK2)	e as m	any sheets	as ne	cessary)		Exa	miner Name				
Sheet	Ī	AMAN 3	3	of	4		Atto	orney Docket Numbe	er 2140	MP		
Sheet	<u> </u>			Ů1			Atto	mey Bocket Ivalilot	2170	/1	/	
	,					J.S. PA	TEN	T DOCUMENTS	S			
Examiner Initials*	Cite No.		U.S. P		Document ()	Kind Code (known)		Name of Patento of Cited D		licant	Date of Publication of Cited Document MM-DD-YYYY	
17.5 F 1			MAN	•								
	ļ	ļ		MARKET								
				***	<b>\</b>							
-	<u> </u>	<u> </u>			1			· · · · · · · · · · · · · · · · · · ·				
		<del> </del>			***************************************	+						
	-	<u> </u>			*							
										<del></del>		
		<del> </del>					A A A A A A A A A A A A A A A A A A A					
		<u> </u>					B. Anna					
							- 8			-		
		<del> </del>			,	-		X				
	<del>                                     </del>	<del>                                     </del>										
							A STATE OF THE STA					
				-			A CONTRACTOR OF THE PARTY OF TH					
						A STATE OF THE STA		1				
								*	1			
			···						M	•		
		L <u>.</u>							M			
					AOBRIG	N PA'	TENT	T DOCUMENTS		<u> </u>		
B	<u> </u>		Forei	ign Pat	nt Document	I A					Date of Publication of	
Examiner Initials*	Cite No.	Office		Ŋm		(	Kind Code known)		d Docum		Cited Document MM-DD-YYYY	
	21		WO 2005					Merck & Co., Inc		***************************************	02/10/2005	
	22		WO 2005/					Merck & Co., Inc		1 40	05/19/2005	
	23		WO/2005/					Graffinity Pharma			06/23/2005	
	24		WO 2005/ WO 2005/					Graffinity Pharma		IS AG	06/23/2005	
	25 26		WO 2005/ WO 2005/					Merck & Co., Inc			11/17/2005	
	27 \$		WO 2005/					Merck & Co., Inc Astrazeneca AB	··		12/08/2005	
	2,	101	** 0 2003/	12300	JAI			Asuazeneca AB		-	12/29/2003	
	A CONTRACTOR OF THE PARTY OF TH			<del></del>								

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

/Brenda Coleman/

Date Considered

09/14/2008

	Substitute for form 1449B/PTO			COMPLETE IF KNOWN				
A. A	INFORMATION DISCLOSURE		Application Number	10/556,805				
N. A.		<b>3</b> 7 A D	DI ICANIT	Filing Date	November 14, 2005			
N. S.	STATEMENT B	x Ar	PLICANI	First Named Inventor	Tesfaye Biftu, et al			
				Group Art Unit				
	(se as many shee	ets as n	ecessary)	Examiner Name				
Shee	t 4	of	4	Attorney Docket Number	21404P			

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	1	Augustyns, K. et al., "Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes" Expert Opin. Ther. Patents, Vol. 13, No. 4, pp 499-510, 2003
	2	Augustyns, K. et al., "Inhibitors of proline-specific dipeptidyl peptidases: DPF IV inhibitors as a novel approach for the treatment of Type 2 diabetes" Expert Opin. Ther. Patents, Vol. 15, No. 10, pp 1387-1407, 2005
	3	Deacon, C. F., "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1" Diabetes, Vol. 53, pp 2181-2189, 2004
	4	Deacon, C. F. et al., "Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?" Expert Opia. Investig. Drugs, Vol. 13, No. 9, pp 1091-1102, 2004
	5	Drucker, D. J., "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes" Expert Opin. Investig. Drugs, Vol. 12, No. 1, pp 87-100, 2003
	6	Holst, J. J., "Treatment of Type 2 diabetes hellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors" Expert Opin. Emerg. Drugs, Vol. 3, No. 1, pp 155-166, 2004
	7	Knudsen, L. B., "Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes" J. Med. Chem, Vol. 47, pp 4128-4134, 2004
	8	Novartis AG: WO0034241 - "Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus", Exp. Opin. Ther. Patents, Vol. 10, No. 12, pp 1937-1942, 2000
	9	Vahl, T. P. et al., "Gut peptides in the treatment of diabetes meditus", Expert Opin. Investig. Drugs, Vol. 13, No. 3, pp 177-188, 2004
	10	Holst, J. J. et al., "Glucagen-like peptide 1 and inhibitors of dipeptidal peptidase IV in the treatment of type 2 diabetes mellitus" Current Opinion in Pharmacology, Vol. 4, pp 589-596, 2004
	11	Demuth, H. U. et al., "Type 2 diabetes-Therapy with dipeptidyl peptidase IV inhibitors" Biochimica et Biophysica Acta, Vol. 1751, pp 33-44, 2005
	12	Weber, A. E. "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes" Med. Chem, Vol. 47, pp 4135-4141 2004

Examiner Signature	/Brenda Coleman/	Date Considered	09/14/2008